Prognosis of Type 2 Diabetic Patients (ARTEMIS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01426685|
Recruitment Status : Active, not recruiting
First Posted : August 31, 2011
Last Update Posted : December 10, 2015
|Condition or disease|
|Cardiovascular Risk Assessment|
Specific aims of the study:
- To compare several autonomic, electric and metabolic risk markers in a case-control study between the patients with coronary artery disease with and without type II diabetes at the time of diagnosis of CAD.
- To assess the prognostic significance of autonomic markers, electrical markers, coronary angiographic markers and metabolic markers in predicting the cardiac events among the CAD patients with and without diabetes
- To develop and test the feasibility of home-monitoring of biosignals among the type II diabetic patients with CAD.
- To further explore the molecular, cellular and genetic factors that predispose diabetics to cardiovascular diseases.
- To develop new methods for the early clinical diagnosis of vulnerable subjects susceptible to the complications of the coronary artery disease in Type 2 diabetes.
5. To assess the effects of controlled exercise training programs to several autonomic, electrical and metabolic risk markers among the type II diabetic patients with CAD
|Study Type :||Observational|
|Actual Enrollment :||1880 participants|
|Official Title:||Prediction of Cardiovascular Events in Type 2 Diabetic Patients With Coronary Artery Disease- Application of Novel Risk Markers and Technology|
|Study Start Date :||August 2007|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
- sudden cardiac death [ Time Frame: 2007-2017 (up to ten years) ]Death occuurring within one hour after onset of symptoms, or within 24 hours when the patient has last seen alive
- cardiovascular mortality [ Time Frame: 2007-2017 (up to ten years) ]Sudden and non-sudden cardiac death, stroke mortality
- non-fatal cardiovascular event [ Time Frame: 2007-2017 (up to ten years) ]acute coronary event, myocardial infarction, congestive heart failure, or stroke needing hospitalization
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01426685
|University of Oulu|
|Oulu, Finland, 90014|
|Principal Investigator:||Heikki V Huikuri, MD||University of Oulu|